One limitation of our study is that we could not determine the type of ROS was involved in the SIRT1-mediated inflammation in LPS-treated CML cells, due to the nonspecific property of DCFH-DA assay and ROS scavenger NAC. This evidence concerns the gene SIRT1 and chronic myelogenous leukemia, BCR-ABL1 positive.